245 related articles for article (PubMed ID: 30368639)
21. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study.
Khanna D; Clements PJ; Furst DE; Chon Y; Elashoff R; Roth MD; Sterz MG; Chung J; FitzGerald JD; Seibold JR; Varga J; Theodore A; Wigley FM; Silver RM; Steen VD; Mayes MD; Connolly MK; Fessler BJ; Rothfield NF; Mubarak K; Molitor J; Tashkin DP;
Arthritis Rheum; 2005 Feb; 52(2):592-600. PubMed ID: 15692967
[TBL] [Abstract][Full Text] [Related]
22. Prognostic and pathophysiological marker for patients with chronic thromboembolic pulmonary hypertension: Usefulness of diffusing capacity for carbon monoxide at diagnosis.
Suda R; Tanabe N; Ishida K; Kato F; Urushibara T; Sekine A; Nishimura R; Jujo T; Sugiura T; Shigeta A; Sakao S; Tatsumi K
Respirology; 2017 Jan; 22(1):179-186. PubMed ID: 27614712
[TBL] [Abstract][Full Text] [Related]
23. Performance capacity evaluated using the 6-minute walk test: 5-year results in patients with diffuse systemic sclerosis and initial interstitial lung disease.
Rizzi M; Sarzi-Puttini P; Airoldi A; Antivalle M; Battellino M; Atzeni F
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S142-7. PubMed ID: 26339893
[TBL] [Abstract][Full Text] [Related]
24. Interstitial lung disease increases mortality in systemic sclerosis patients with pulmonary arterial hypertension without affecting hemodynamics and exercise capacity.
Michelfelder M; Becker M; Riedlinger A; Siegert E; Drömann D; Yu X; Petersen F; Riemekasten G
Clin Rheumatol; 2017 Feb; 36(2):381-390. PubMed ID: 28028682
[TBL] [Abstract][Full Text] [Related]
25. Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease.
Launay D; Humbert M; Berezne A; Cottin V; Allanore Y; Couderc LJ; Bletry O; Yaici A; Hatron PY; Mouthon L; Le Pavec J; Clerson P; Hachulla E
Chest; 2011 Oct; 140(4):1016-1024. PubMed ID: 21474572
[TBL] [Abstract][Full Text] [Related]
26. Lung function is associated with minimal EQ-5D changes over time in patients with systemic sclerosis.
Ciaffi J; van Leeuwen NM; Liem SIE; Ninaber MK; Huizinga TWJ; de Vries-Bouwstra JK
Clin Rheumatol; 2020 May; 39(5):1543-1549. PubMed ID: 31980971
[TBL] [Abstract][Full Text] [Related]
27. Value of lung diffusing capacity for nitric oxide in systemic sclerosis.
Barisione G; Garlaschi A; Occhipinti M; Baroffio M; Pistolesi M; Brusasco V
Physiol Rep; 2019 Aug; 7(13):e14149. PubMed ID: 31264386
[TBL] [Abstract][Full Text] [Related]
28. Pulmonary arterial hypertension in systemic sclerosis: the need for early detection and treatment.
Proudman SM; Stevens WM; Sahhar J; Celermajer D
Intern Med J; 2007 Jul; 37(7):485-94. PubMed ID: 17547726
[TBL] [Abstract][Full Text] [Related]
29. Detection of interstitial lung disease in systemic sclerosis through partitioning of lung transfer for carbon monoxide.
Pernot J; Puzenat E; Magy-Bertrand N; Manzoni P; Gondouin A; Bourdin H; Simon-Rigaud ML; Regnard J; Degano B
Respiration; 2012; 84(6):461-8. PubMed ID: 22301769
[TBL] [Abstract][Full Text] [Related]
30. Quantifying change in pulmonary function as a prognostic marker in systemic sclerosis-related interstitial lung disease.
Moore OA; Proudman SM; Goh N; Corte TJ; Rouse H; Hennessy O; Morrisroe K; Thakkar V; Sahhar J; Roddy J; Youssef P; Gabbay E; Nash P; Zochling J; Stevens W; Nikpour M
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S111-6. PubMed ID: 26243401
[TBL] [Abstract][Full Text] [Related]
31. The clinical significance of serum N-terminal pro-brain natriuretic peptide in systemic sclerosis patients.
Choi HJ; Shin YK; Lee HJ; Kee JY; Shin DW; Lee EY; Lee YJ; Lee EB; Song YW
Clin Rheumatol; 2008 Apr; 27(4):437-42. PubMed ID: 17899307
[TBL] [Abstract][Full Text] [Related]
32. Idiopathic and Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: A Comparison of Demographic, Hemodynamic, and MRI Characteristics and Outcomes.
Ramjug S; Hussain N; Hurdman J; Billings C; Charalampopoulos A; Elliot CA; Kiely DG; Sabroe I; Rajaram S; Swift AJ; Condliffe R
Chest; 2017 Jul; 152(1):92-102. PubMed ID: 28223154
[TBL] [Abstract][Full Text] [Related]
33. Effects of micronutrient antioxidants (alpha-tocopherol and ascorbic acid) on skin thickening and lung function in patients with early diffuse systemic sclerosis.
Ostojic P; Damjanov N
Rheumatol Int; 2011 Aug; 31(8):1051-4. PubMed ID: 20309694
[TBL] [Abstract][Full Text] [Related]
34. A longitudinal study of pulmonary function in Danish patients with systemic sclerosis.
Jacobsen S; Halberg P; Ullman S; Høier-Madsen M; Petersen J; Mortensen J; Wiik A
Clin Rheumatol; 1997 Jun; 16(4):384-90. PubMed ID: 9259253
[TBL] [Abstract][Full Text] [Related]
35. Pulmonary arterial hypertension and systemic sclerosis relation: a single centre experience.
Demir N; Şahin A; Küçükşahin O; Kayacan O; Dinçer İ; Sayın T; Karnak D; Turgay M
Heart Lung Circ; 2014 Jul; 23(7):667-73. PubMed ID: 24613044
[TBL] [Abstract][Full Text] [Related]
36. Subspecificities of anticentromeric protein A antibodies identify systemic sclerosis patients at higher risk of pulmonary vascular disease.
Perosa F; Favoino E; Favia IE; Vettori S; Prete M; Corrado A; Cantatore FP; Valentini G
Medicine (Baltimore); 2016 Jun; 95(25):e3931. PubMed ID: 27336883
[TBL] [Abstract][Full Text] [Related]
37. Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): baseline characteristics and description of study population.
Hinchcliff M; Fischer A; Schiopu E; Steen VD;
J Rheumatol; 2011 Oct; 38(10):2172-9. PubMed ID: 21844142
[TBL] [Abstract][Full Text] [Related]
38. Exercise-induced pulmonary arterial hypertension in patients with systemic sclerosis.
Steen V; Chou M; Shanmugam V; Mathias M; Kuru T; Morrissey R
Chest; 2008 Jul; 134(1):146-51. PubMed ID: 18403670
[TBL] [Abstract][Full Text] [Related]
39. Does reduced lung diffusing capacity for carbon monoxide predict the presence of pulmonary hypertension?
Delcour KS; Singla A; Jarbou M; Alpert M; Dabbagh O
Am J Med Sci; 2010 Jul; 340(1):54-9. PubMed ID: 20463574
[TBL] [Abstract][Full Text] [Related]
40. Improvement of lung function in patients with systemic sclerosis after 6 months cyclophosphamide pulse therapy.
Ostojic P; Damjanov N
Clin Rheumatol; 2006 Nov; 25(6):819-21. PubMed ID: 16440134
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
